Loading...
XCNQ
BIOV
Market cap7mUSD
Jun 09, Last price  
0.04CAD
1D
0.00%
1Q
-30.00%
IPO
-33.33%
Name

Biovaxys Technology Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L-60.29%
-230,334-1,178,549-6,473,845-19,357,324-7,687,317
CFO
-2m
L+76.54%
-230,759-1,226,885-5,294,426-1,574,609-1,054,848-1,862,237

Profile

BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
IPO date
Nov 21, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑10
Income
Revenues
Cost of revenue
2,403
4,082
Unusual Expense (Income)
NOPBT
(2,403)
(4,082)
NOPBT Margin
Operating Taxes
7,630
Tax Rate
NOPAT
(2,403)
(11,712)
Net income
(7,687)
-60.29%
(19,357)
199.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,161
917
1,108
BB yield
-5.51%
Debt
Debt current
68
Long-term debt
Deferred revenue
Other long-term liabilities
1,313
Net debt
(144)
(977)
(293)
Cash flow
Cash from operating activities
(1,862)
(1,055)
(1,575)
CAPEX
(1,056)
Cash from investing activities
(1,056)
Cash from financing activities
3,127
917
1,108
FCF
(1,608)
132
(10,787)
Balance
Cash
212
977
142
Long term investments
151
Excess cash
212
977
293
Stockholders' equity
(1,943)
(3,372)
(774)
Invested Capital
91
ROIC
ROCE
71.25%
527.68%
EV
Common stock shares outstanding
134,143
98,180
Price
0.07
 
0.21
-44.59%
Market cap
20,127
-34.41%
EV
19,834
EBITDA
(2,403)
(4,082)
EV/EBITDA
Interest
16
Interest/NOPBT